• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Delta Air eyes mid single-digit revenue growth in 2025 with premium travel in focus

by November 20, 2024
written by November 20, 2024

(Reuters) – Delta Air Lines (NYSE:DAL) said on Wednesday it expects 2025 revenue to grow by a mid single-digit percentage as it strengthens its bet on premium travel, a major revenue driver for the carrier.

The airline added that affluent customers were thriving with leisure travel being the highest priority purchase for high-income households.

Premium travel has been on the rise since the pandemic, with consumers preferring to pay extra dollars for amenities such as more comfortable seats.

Premium seating, which previously depended heavily on corporate bookings, is now seeing increased interest from individual travelers.

Delta Air said it is targeting profit per share to increase 10% in the next three to five years, and expects operating margins to be in the mid-teens percentage.

The Atlanta-based company expects its high-margin premium offerings to outpace its main cabin by 2027.

That opens up avenues for the carrier to grow revenue through non-ticket sources such as airline-branded credit card fees, checked bags and extra legroom.

Delta also forecast 2025 capacity growth between 3% and 4%. The carrier’s shares fell nearly 1% before the bell suggesting investor worries about effects of excess capacity on air fares.

An excess supply of airline seats in the U.S. market during the summer travel season had forced carriers to discount fares to fill their planes, hurting their earnings.

However, measures taken by airlines to moderate capacity growth have since aided pricing power.

Delta Air’s investor day is scheduled on Wednesday where it is expected to provide further details on its long-term financial targets.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
China’s Pony AI seeks up to $4.55 billion valuation in upsized US IPO
next post
Pfizer names oncology head Chris Boshoff as R&D chief

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Musk’s brain implant company filed as a ‘disadvantaged business’

      July 19, 2025
    • A flagging U.S. industry looks for new life in a Philadelphia shipyard

      July 18, 2025
    • Coca-Cola dodges after Trump says soda will switch back to cane sugar

      July 18, 2025
    • Trump says it’s ‘highly unlikely’ he will fire Fed Chair after broaching idea with GOP reps

      July 17, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (562)
    • Stock (6,426)

    Latest News

    • Musk’s brain implant company filed as a ‘disadvantaged business’
    • A flagging U.S. industry looks for new life in a Philadelphia shipyard

    Popular News

    • Sri Lanka c. bank to focus on stronger crisis recovery in 2025
    • SAIC Motor sees up to 90% drop in 2024 profits

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy